吉利汽车(00175):2025年12月销量点评:超额完成全年目标,极氪9X月交付过万
Changjiang Securities· 2026-01-06 09:45
丨证券研究报告丨 分析师及联系人 [Table_Author] [Table_scodeMsg1] 港股研究丨公司点评丨吉利汽车(00175.HK) [Table_Title] 吉利汽车 2025 年 12 月销量点评:超额完成全 年目标,极氪 9X 月交付过万 高伊楠 张扬 SAC:S0490517060001 SAC:S0490524030004 SFC:BUW101 请阅读最后评级说明和重要声明 报告要点 [Table_Summary] 吉利汽车发布 2025 年 12 月销量。公司 12 月销量 23.7 万辆,同比+12.7%,环比-23.7%。2025 年全年累计销量 302.5 万辆,同比+39.0%。新平台赋能,吉利汽车有望开启产品新时代。GEA 架构支撑新车周期,极氪、领克、银河全面向好。各品牌新能源转型顺利推进,规模效应逐步 凸显将带来盈利向上弹性。公司燃油车基盘稳固,联营企业创新出海模式持续打开海外新空间。 智能化战略即将开启,加速提升智驾能力。整车强势新周期下盈利具备较大弹性。 %% %% %% %% research.95579.com 1 [Table_scodeMsg2] 吉利汽 ...
兆易创新(03986):兆易创新(03986):IPO点评
国投证券(香港)· 2026-01-06 09:36
Investment Rating - The report assigns an IPO-specific rating of 5.9 out of 10 for the company, based on operational performance, industry outlook, offering valuation, and market sentiment [7]. Core Insights - The company, founded in 2005, operates under a fabless model focusing on integrated circuit design, with core products including specialized memory chips, MCUs, analog chips, and sensor chips, serving various sectors such as consumer electronics, automotive, and IoT [1]. - The semiconductor industry is characterized by significant cyclicality, with a recovery expected starting in 2024 after a downturn in 2023, driven by uneven market recovery and AI applications [3]. - The company holds leading positions in several market segments, including NOR Flash and SLC NAND Flash, with a strong emphasis on R&D and strategic acquisitions to enhance its product offerings and market presence [4]. Financial Summary - Revenue projections for 2022 to 2025 show a decline from 81.30 billion CNY in 2022 to 57.61 billion CNY in 2023, followed by a recovery to 73.56 billion CNY in 2024, with net profits expected to follow a similar trend [2]. - The gross margin is anticipated to gradually recover to 36.9% by mid-2025, with net asset value increasing to 174.35 billion CNY [2]. Industry Status and Outlook - The semiconductor industry is experiencing a downturn in 2023 due to normalized demand post-pandemic, but signs of recovery are expected in 2024, particularly in AI-driven applications [3]. - The competitive landscape in the NOR Flash, SLC NAND Flash, and niche DRAM markets is concentrated, with the top three players holding significant market shares [3]. Strengths and Opportunities - The company benefits from a strong market position, diverse product matrix, and a robust R&D team, with over 15% of revenue allocated to R&D in 2023-2024 [4]. - The rise of edge AI is expected to create additional demand for the company's products, with strategic acquisitions enhancing its capabilities in the analog chip sector [4]. Weaknesses and Risks - The company faces intense market competition and reliance on third-party manufacturing, which may impact pricing and profitability [5][6]. - High supplier concentration poses risks, as the company depends heavily on a limited number of core partners for production [9].
朝云集团(06601):跟踪点评:拟收购河北康达,加码北方家居护理市场
GUOTAI HAITONG SECURITIES· 2026-01-06 08:55
拟收购河北康达,加码北方家居护理市场 朝云集团(6601) 朝云集团公司跟踪点评 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 刘佳昆(分析师) | 021-38038184 | liujiakun@gtht.com | S0880524040004 | | 毛宇翔(分析师) | 021-38038672 | maoyuxiang@gtht.com | S0880524080013 | 本报告导读: 朝云集团收购河北康达,加码北方家居护理市场,双品牌协同赋能增长。 [Table_Industry] 耐用消费品 | [Table_Invest] 评级: | 增持 | | --- | --- | | [当前价格 Table_CurPrice] (港元): | 2.24 | [Table_Market] 交易数据 | 52 周内股价区间(港元) | 1.76-3.09 | | --- | --- | | 当前股本(百万股) | 1,333 | | 当前市值(百万港元) | 2,987 | [Table_PicQuote] 52周 ...
小鹏汽车-W(09868):强势产品周期开启战略转型,“物理AI”公司
NORTHEAST SECURITIES· 2026-01-06 08:40
Investment Rating - The report assigns a "Buy" rating for the company [7] Core Insights - The company achieved total revenue of 20.38 billion yuan in Q3 2025, a year-on-year increase of 101.8%, with net loss significantly narrowing to 0.38 billion yuan. Total deliveries reached 116,007 units, up 149.3%, marking a historical high. The comprehensive gross margin exceeded 20% for the first time, reaching 20.1%, indicating a notable improvement in profitability [1][4] - The company has launched a "dual power" strategy combining pure electric and range-extended vehicles to address user range anxiety. The first range-extended model, X9 EREV, was launched in November 2025, featuring a 63.3 kWh battery and a conversion efficiency exceeding 3.6 kWh/L, achieving a pure electric range of 452 km. Additional range-extended versions of key models are expected in Q1 2026, alongside four new models in 2026, including two SUVs based on the MONA platform [2] - The company is transitioning from "smart cars" to a "physical AI" company, showcasing its commitment and specific path at the 2025 Technology Day. The core technology, VLA 2.0, enhances reasoning efficiency by 12 times and improves average takeover mileage in complex scenarios by 13 times. The model is set to be fully deployed in Ultra models by Q1 2026 and is expected to extend to robotics and other embodied intelligence fields [3] - The company forecasts revenues of 75.8 billion yuan, 132.1 billion yuan, and 166.3 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 85.4%, 74.3%, and 25.9%. The net profit attributable to the parent company is projected to be -1.55 billion yuan, 2.00 billion yuan, and 6.13 billion yuan for the same years [4][5]
港铁公司(00066):紧扣香港景气脉搏,“铁路+物业”模式助推发展
Shenwan Hongyuan Securities· 2026-01-06 06:03
Investment Rating - The report initiates coverage with a rating of "Buy" for MTR Corporation [2][6] Core Insights - MTR Corporation has established itself as the core operator of Hong Kong's rail transit since its inception in 1975, with a significant focus on local line construction and expansion into international markets [5][16] - The "Rail + Property" development model allows MTR to finance railway projects through land development rights granted by the government, which is expected to drive long-term growth as the Hong Kong real estate market recovers [5][47] - The company has a progressive dividend policy, with expected dividends per share increasing from HKD 1.06 in 2015 to HKD 1.31 in 2024, maintaining dividends even during losses [5][43] Financial Data and Profit Forecast - Revenue projections for MTR Corporation are as follows: - 2023: HKD 56,982 million - 2024: HKD 60,011 million - 2025E: HKD 57,117 million - 2026E: HKD 55,584 million - 2027E: HKD 58,152 million - Net profit attributable to shareholders is forecasted as: - 2023: HKD 7,784 million - 2024: HKD 15,772 million - 2025E: HKD 16,203 million - 2026E: HKD 20,166 million - 2027E: HKD 10,138 million - The company is expected to maintain a dividend yield of approximately 4.4% from 2025 to 2027 [4][6] Business Model and Operations - MTR Corporation operates under a "Rail + Property" model, which integrates railway operations with property development to fund infrastructure projects [5][47] - The company is actively involved in multiple new railway and station projects to enhance connectivity in densely populated areas of Hong Kong [51][52] - The Hong Kong rail operations are expected to see a recovery in passenger numbers, with total passenger volume projected to reach 1.953 billion in 2024, recovering towards pre-pandemic levels [79] Valuation and Target Price - The estimated enterprise value of MTR Corporation is HKD 2,766 billion, with a 20% discount applied due to diversified operations, leading to a target equity value of HKD 2,213 billion [6] - The target price is set at HKD 35.55 per share, indicating a potential upside of 19% from the current market value [6]
京东健康(06618):4Q25前瞻:强劲的收入增速延续
HTSC· 2026-01-06 03:36
Investment Rating - The report maintains a "Buy" rating for JD Health with a target price of HKD 77.40 [7][18]. Core Insights - JD Health is expected to continue strong revenue growth in 4Q25, with a projected year-on-year increase of 22.7% to RMB 20.26 billion, driven by the increasing online penetration of pharmaceuticals and the company's competitive advantages in supply chain management [2][15]. - The company is anticipated to achieve a non-IFRS operating profit of RMB 260 million in 4Q25, reflecting a non-IFRS operating profit margin of 1.3%, an improvement of 0.4 percentage points year-on-year [2]. - The report highlights the importance of monitoring the supply iteration of new medical products, the impact of weight-loss drugs entering the medical insurance list, the penetration of AI medical applications, and the expansion of JD Health's O2O business [1]. Revenue and Profit Forecast - JD Health's total revenue for 4Q25 is expected to grow by 22.7% year-on-year to RMB 20.26 billion, with pharmaceuticals projected to see over 30% growth in GMV [2][15]. - For the full year of 2025, revenue is forecasted to increase by 25% to RMB 72.7 billion, with a non-IFRS operating profit of RMB 4.11 billion, corresponding to a non-IFRS operating profit margin of 5.7%, an improvement of 1.2 percentage points year-on-year [2][15]. Offline Business Development - JD Health is set to open over 200 new offline pharmacy stores in the second half of 2025, with 150 stores expected to open in 4Q25, enhancing user reach and brand exposure [3]. - The company's medical insurance payment coverage has expanded to 8 cities, including Shanghai, which is anticipated to drive user penetration and performance growth [3]. New Product Launches and AI Integration - JD Health continues to strengthen partnerships with upstream medical brands, achieving multiple collaborations for new drug launches, thereby enhancing its channel value [4]. - The report notes the positive reception of JD Health's AI doctor, which has achieved a satisfaction rate of 98%, reinforcing its capabilities in internet medical services [4]. Profitability Adjustments - The profit forecasts for 2025-2027 have been raised by 11.6%, 15.6%, and 22.4% respectively, due to improved revenue expectations and the anticipated release of operating leverage [5][15]. - The target valuation for 2026 has been adjusted to a non-IFRS PE of 30.0x, reflecting a premium over comparable companies, driven by JD Health's efficiency in the pharmaceutical market and its advantages in AI medical applications [18].
小鹏汽车-W(09868):港股研究|公司点评|小鹏汽车-W(09868.HK):小鹏汽车2025年12月销量点评:总交付3.75万辆,同环比增长,X9交付强势
Changjiang Securities· 2026-01-05 23:30
Investment Rating - The investment rating for the company is "Buy" and it is maintained [6]. Core Insights - The company delivered a total of 37,508 vehicles in December 2025, representing a year-on-year increase of 2.2% and a month-on-month increase of 2.1% [2][4]. - For the entire year of 2025, the company achieved cumulative deliveries of 429,000 vehicles, marking a significant year-on-year growth of 125.9% [2][4]. - The launch of the new X9 model has been particularly strong, with 5,424 units delivered in December, achieving a month-on-month increase of 68% and a year-on-year increase of 289% [6]. - The company is expected to continue its growth trajectory with new models like the P7+ and G7 set to be released, enhancing its sales cycle [6]. - The overseas market has also shown promising growth, with 45,000 vehicles delivered internationally in 2025, reflecting a year-on-year increase of 96% [6]. - The company anticipates Q4 2025 deliveries to be between 125,000 and 132,000 units, which would represent a year-on-year growth of 36.6% to 44.3% [6]. Summary by Relevant Sections Sales Performance - December 2025 deliveries totaled 37,508 vehicles, with a year-on-year growth of 2.2% and a month-on-month growth of 2.1% [2][4]. - Cumulative deliveries for 2025 reached 429,000 vehicles, up 125.9% year-on-year [2][4]. New Product Launches - The X9 model has seen strong performance, with December deliveries reaching 5,424 units, marking a record for the model [6]. - Upcoming releases of the P7+ and G7 models are expected to further boost sales [6]. International Expansion - The company delivered 45,000 vehicles in international markets in 2025, a 96% increase year-on-year [6]. - The company has established a presence in 60 countries and regions globally, with local production in Malaysia starting in December 2025 [6]. Future Outlook - The company is positioned for significant revenue growth, with projected revenues of approximately 75.1 billion and 112.1 billion for 2025 and 2026, respectively [6]. - The anticipated price-to-sales ratios for 2025 and 2026 are 1.8 and 1.2, respectively, supporting the "Buy" rating [6].
深圳国际(00152):转型升级项目持续兑现,高股息价值凸显:深圳国际(00152.HK)
Hua Yuan Zheng Quan· 2026-01-05 14:25
Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The transformation and upgrade projects are continuously being realized, highlighting the value of high dividends [5] - The company has a stable dividend policy, with a payout ratio increasing from around 40% (2013-2016) to approximately 50% (2017-2024), with total dividends of 11.8 billion HKD during 2018-2024 [7] - The company is expected to see profit growth from its logistics park transformation projects, with projected net profits of 36.4 billion, 36.5 billion, and 28.0 billion HKD for 2025-2027, corresponding to P/E ratios of 5.8, 5.8, and 7.5 respectively [7] Financial Performance - Revenue projections for the company are as follows: 20,523.8 million HKD in 2023, decreasing to 15,570.6 million HKD in 2024, and then gradually increasing to 17,250.2 million HKD by 2027, with a CAGR of 5.2% from 2026 to 2027 [6] - The net profit attributable to shareholders is forecasted to be 1,901.6 million HKD in 2023, increasing to 3,637.9 million HKD in 2025, before declining to 2,795.9 million HKD in 2027 [6] - The company's earnings per share (EPS) is expected to be 0.80 HKD in 2023, reaching 1.49 HKD in 2025, and then slightly decreasing to 1.14 HKD in 2027 [6] Market Data - The closing price of the company's stock is 8.60 HKD, with a market capitalization of 21,016.13 million HKD [3] - The company's asset-liability ratio stands at 58.62% [3]
快手-W(01024):可灵迭代用户有望增长,One 系列模型持续提振主业
Shenwan Hongyuan Securities· 2026-01-05 12:18
品可以分分或叫 2026 年 01 月 05 日 #== W (01024) 可灵迭代用户有望增长, One 系列模型持续提振主业 报告原因:强调原有的投资评级 ( | 市场数据: | 2026 年 01 月 02 日 | | --- | --- | | 收盘价(港币) | 66.25 | | 恒生中国企业指数 | 9168.99 | | 52 周最高/最低(港币) | 92.60/38.15 | | H 股市值(亿港币) | 2.861.66 | | 流通 H 股(百万股) | 4.319.48 | | 汇率(港币/人民币) | 0.9032 | 年内股价与基准指数对比走势: 资料来源:Bloomberg 相关研究 证券分析师 林起贤 A0230519060002 linqx@swsresearch.com 任梦妮 A0230521100005 renmn@swsresearch.com 联系人 任梦妮 A0230521100005 renmn@swsresearch.com 申万宏源研究微信服务号 投资要点: 财务数据及盈利预测 | | 2023A | 2024A | 2025E | 2026E | 20 ...
金浔资源(03636):IPO点评报告
国投证券(香港)· 2026-01-05 11:34
Investment Rating - The report assigns a rating of "5.7" to the company, suggesting it is worth attention [12]. Core Insights - The company is a high-quality cathode copper manufacturer, ranking fifth among Chinese producers and is the only Chinese company in the top five in both the Democratic Republic of Congo (DRC) and Zambia [1]. - The company has experienced rapid sales growth, with total sales increasing from 7,056.7 tons in 2022 to 19,868.9 tons in 2024, representing a compound annual growth rate (CAGR) of +67.8% [2]. - The global cathode copper market is expected to see a supply shortage of approximately 5.8 million tons by 2029, which is likely to drive up copper prices [3]. - The company benefits from a strong business presence in resource-rich regions of Africa, particularly in DRC and Zambia, and has a strategic capacity layout that aligns with China's "going out" strategy [4]. Company Overview - The company produced approximately 16,000 tons of cathode copper in DRC and 5,000 tons in Zambia in 2024, with a market share of 0.9% in DRC and ranking first in Zambia [1]. - The company’s revenue for 2022, 2023, and 2024 was approximately RMB 637.3 million, RMB 675.7 million, and RMB 1,769.8 million, respectively, with a CAGR of +66.7% [2]. - The company has four production facilities, including two copper smelters in Zambia and one in DRC, and is constructing a cobalt processing plant in China [12]. Industry Status and Outlook - The downstream applications for cathode copper include deep processing enterprises, trading companies, and sectors such as new energy and electronics manufacturing [3]. - Global cathode copper production is projected to grow from 21.9 million tons in 2025 to 24.7 million tons by 2029, with a CAGR of 3.0% [3]. - The average copper price in China is expected to rise from RMB 749,000 in 2024 to RMB 775,000 in 2025 [3]. Use of Proceeds - Approximately 80% of the funds raised (or HKD 834.1 million) will be used to expand core business operations, including enhancing the wet metallurgy capacity of the DRC copper smelter and increasing cobalt hydroxide production lines [6]. Cornerstone Investors - Key cornerstone investors include Glencore, Stoneylake Global, North Rock, and others, with total subscriptions amounting to USD 60.255 million, representing 42.50% of the shares offered [7].